2002 Leads Networking Pharmaceutical research 
PharmaKinnex
AUGUST 23, 2022
Bearing the brunt of these COVID19 restrictions, pharmaceutical reps have had a hard time getting in the door to make sales, and their employers have noticed: Limited In-Person Access To HCPs. Fewer Networking & Industry Trade Show Events. Higher Travel & Marketing Costs. Increased Product & Legal Knowledge Requirements.
European Pharmaceutical Review
SEPTEMBER 22, 2023
Targeting toxic species of Abeta, such as multimers (with aducanumab and lecanemab) or pyroglutamate Abeta3-42 (with donanemab), induced significant removal of Abeta plaque load in the brains of Alzheimer’s patients, leading to the delay in cognitive decline. Treatment with the mAbs delayed cognitive decline by 2.6 months for lecanemab and 5.5
Expert insights. Personalized for you.
52 
Let's personalize your content